DK170360B1 - Antipsykotiske formuleringer indeholdende dioxopiperidinderivater - Google Patents

Antipsykotiske formuleringer indeholdende dioxopiperidinderivater Download PDF

Info

Publication number: DK170360B1
Authority: DK; Denmark
Prior art keywords: alkyl; methyl; hydrogen; compound; formula
Prior art date: 1987-07-10

Application number

DK382588A

Other languages

Danish (da)

English (en)

Other versions

DK382588D0 (da

DK382588A (da

Inventor

Brenda Costall

Original Assignee

British Tech Group

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-10

Filing date

1988-07-08

Publication date

1995-08-14

1988-07-08 Application filed by British Tech Group filed Critical British Tech Group

1988-07-08 Publication of DK382588D0 publication Critical patent/DK382588D0/da

1989-01-11 Publication of DK382588A publication Critical patent/DK382588A/da

1995-08-14 Application granted granted Critical

1995-08-14 Publication of DK170360B1 publication Critical patent/DK170360B1/da

Links

239000000203 mixture Substances 0.000 title description 9
230000000561 anti-psychotic effect Effects 0.000 title description 6
CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical class O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 title description 2
238000009472 formulation Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 48
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 35
239000001257 hydrogen Substances 0.000 claims abstract description 35
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 23
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 22
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
125000000217 alkyl group Chemical group 0.000 claims abstract description 17
125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
238000011282 treatment Methods 0.000 claims abstract description 11
150000002367 halogens Chemical class 0.000 claims abstract description 6
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 18
150000002431 hydrogen Chemical class 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 7
208000028017 Psychotic disease Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000000144 pharmacologic effect Effects 0.000 claims description 2
VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 claims 1
UJFNSGBGJMRZKS-UHFFFAOYSA-N agn-2979 Chemical compound COC1=CC=CC(C2(CCCN(C)C)C(CC(=O)NC2=O)(C)C)=C1 UJFNSGBGJMRZKS-UHFFFAOYSA-N 0.000 abstract description 18
230000000694 effects Effects 0.000 abstract description 11
201000000980 schizophrenia Diseases 0.000 abstract description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
239000000932 sedative agent Substances 0.000 abstract 1
230000001624 sedative effect Effects 0.000 abstract 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 48
229960003638 dopamine Drugs 0.000 description 25
208000013403 hyperactivity Diseases 0.000 description 13
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 11
229960002690 fluphenazine Drugs 0.000 description 11
239000003826 tablet Substances 0.000 description 9
241000700159 Rattus Species 0.000 description 8
239000002775 capsule Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
239000004020 conductor Substances 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
210000001009 nucleus accumben Anatomy 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000000949 anxiolytic effect Effects 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
230000006742 locomotor activity Effects 0.000 description 4
125000004433 nitrogen atom Chemical group N* 0.000 description 4
125000003386 piperidinyl group Chemical group 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004300 GABA-A Receptors Human genes 0.000 description 3
108090000839 GABA-A Receptors Proteins 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
102000005506 Tryptophan Hydroxylase Human genes 0.000 description 3
108010031944 Tryptophan Hydroxylase Proteins 0.000 description 3
239000000164 antipsychotic agent Substances 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000006187 pill Substances 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
238000001061 Dunnett's test Methods 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920005439 Perspex® Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
241000219161 Theobroma Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
239000004296 sodium metabisulphite Substances 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007492 two-way ANOVA Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical group CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
DKCRDQKHMMPWPG-UHFFFAOYSA-N 3-methylpiperidine-2,6-dione Chemical class CC1CCC(=O)NC1=O DKCRDQKHMMPWPG-UHFFFAOYSA-N 0.000 description 1
VKAFLRKLEQIJOF-UHFFFAOYSA-N 4,4-dimethyl-3-[2-(methylamino)ethyl]-3-phenylpiperidine-2,6-dione Chemical compound C=1C=CC=CC=1C1(CCNC)C(=O)NC(=O)CC1(C)C VKAFLRKLEQIJOF-UHFFFAOYSA-N 0.000 description 1
239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
-1 alkaline earth metal salt Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000002932 anti-schizophrenic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
230000000338 anxiogenic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960001149 dopamine hydrochloride Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical group CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
229960002200 flunitrazepam Drugs 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000004898 kneading Methods 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000011707 mineral Substances 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
239000008188 pellet Substances 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)

DK382588A 1987-07-10 1988-07-08 Antipsykotiske formuleringer indeholdende dioxopiperidinderivater DK170360B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878716337A GB8716337D0 (en)	1987-07-10	1987-07-10	Antipsychotic compositions
GB8716337		1988-07-10

Publications (3)

Publication Number	Publication Date
DK382588D0 DK382588D0 (da)	1988-07-08
DK382588A DK382588A (da)	1989-01-11
DK170360B1 true DK170360B1 (da)	1995-08-14

Family

ID=10620478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK382588A DK170360B1 (da)	1987-07-10	1988-07-08	Antipsykotiske formuleringer indeholdende dioxopiperidinderivater

Country Status (12)

Country	Link
US (1)	US4877800A (fr)
EP (1)	EP0298738B1 (fr)
JP (1)	JPS6463516A (fr)
AT (1)	ATE81003T1 (fr)
AU (1)	AU606701B2 (fr)
CA (1)	CA1328077C (fr)
DE (1)	DE3874982T2 (fr)
DK (1)	DK170360B1 (fr)
GB (2)	GB8716337D0 (fr)
IE (1)	IE61536B1 (fr)
PT (1)	PT87954B (fr)
ZA (1)	ZA884937B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5177086A (en) *	1988-11-10	1993-01-05	National Research Development Corporation	Memory-enhancing compositions containing dioxopiperidine derivatives
GB8826308D0 (en) *	1988-11-10	1988-12-14	Nat Res Dev	Memory-enhancing compositions containing dioxopiperidine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1455687A (en) *	1972-12-28	1976-11-17	Aspro Nicholas Ltd	Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
DE3650733T2 (de) *	1985-09-11	2000-05-04	Btg International Ltd., London	Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe
US4705796A (en) *	1986-08-25	1987-11-10	Stereochemical Genetics, Inc.	Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders
DE3779991T2 (de) *	1986-09-08	1993-02-04	British Tech Group	Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.

1987
- 1987-07-10 GB GB878716337A patent/GB8716337D0/en active Pending
1988
- 1988-07-07 EP EP88306207A patent/EP0298738B1/fr not_active Expired - Lifetime
- 1988-07-07 DE DE8888306207T patent/DE3874982T2/de not_active Expired - Fee Related
- 1988-07-07 GB GB8816213A patent/GB2206490B/en not_active Expired - Lifetime
- 1988-07-07 AT AT88306207T patent/ATE81003T1/de not_active IP Right Cessation
- 1988-07-08 ZA ZA884937A patent/ZA884937B/xx unknown
- 1988-07-08 AU AU18861/88A patent/AU606701B2/en not_active Ceased
- 1988-07-08 DK DK382588A patent/DK170360B1/da not_active IP Right Cessation
- 1988-07-08 IE IE208688A patent/IE61536B1/en not_active IP Right Cessation
- 1988-07-08 PT PT87954A patent/PT87954B/pt not_active IP Right Cessation
- 1988-07-11 CA CA000571649A patent/CA1328077C/fr not_active Expired - Fee Related
- 1988-07-11 JP JP63173620A patent/JPS6463516A/ja active Pending
- 1988-07-11 US US07/217,450 patent/US4877800A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT87954A (pt)	1989-06-30
GB2206490A (en)	1989-01-11
IE882086L (en)	1989-01-10
EP0298738A3 (en)	1989-08-09
AU1886188A (en)	1989-01-27
EP0298738B1 (fr)	1992-09-30
US4877800A (en)	1989-10-31
GB8816213D0 (en)	1988-08-10
IE61536B1 (en)	1994-11-16
JPS6463516A (en)	1989-03-09
PT87954B (pt)	1995-03-01
ZA884937B (en)	1990-03-28
DK382588D0 (da)	1988-07-08
DE3874982T2 (de)	1993-04-01
EP0298738A2 (fr)	1989-01-11
GB8716337D0 (en)	1987-08-19
DK382588A (da)	1989-01-11
DE3874982D1 (de)	1992-11-05
AU606701B2 (en)	1991-02-14
ATE81003T1 (de)	1992-10-15
GB2206490B (en)	1991-09-18
CA1328077C (fr)	1994-03-29

Legal Events

Date	Code	Title	Description
1995-08-14	B1	Patent granted (law 1993)
1997-03-24	PBP	Patent lapsed

Publication	Publication Date	Title
EP0216555B1 (fr)	1992-09-02	Utilisation de dérivés de la dioxopipéridine pour le traitement de l'anxiété, pour la réduction des niveaux de la sérotonine ou de l'acide 5-hydroxy-indoleacétique chroniquement anormalement élevés dans le cerveau, et pour le traitement des infections bact
NZ266683A (en)	1996-08-27	Hot melt filling of dosage form using supercooled mycophenolate mofetil, mycophenolic acid or ranolazine liquids
JP2009137970A (ja)	2009-06-25	ミルタザピンと１種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
NZ536603A (en)	2007-06-29	A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of Alzheimer's disease
EP0276559B1 (fr)	1992-08-05	Emploi de dérivés de cétone pour le traitement de la dépression
AU606424B2 (en)	1991-02-07	Use of dioxopiperidine derivatives as analgesics
US4877800A (en)	1989-10-31	Antipsychotic compositions containing dioxopiperidine derivatives
US4259346A (en)	1981-03-31	Bradycardiac pharmaceutical compositions and method of use
KR20010105418A (ko)	2001-11-28	기분 장애 치료용 오사네턴트
KR20050038014A (ko)	2005-04-25	피페리딘-2,6-디온 파모에이트 염 및 스트레스 관련 정동장애의 치료를 위한 이의 용도
WO1998004261A1 (fr)	1998-02-05	Utilisation de la nefazodone dans la prophylaxie de la migraine
WO1995028933A1 (fr)	1995-11-02	Utilisation de derives arylpiperazines dans le traitement de la maladie de parkinson et de psychoses
US4105796A (en)	1978-08-08	Pharmaceutical compositions containing racemic or optically active 1-(2,6-dimethyl-phenoxy)-2-methylamino-propane and method of use
US4363809A (en)	1982-12-14	Organic compounds
AU620658B2 (en)	1992-02-20	Memory-enhancing compositions containing dioxopiperidine derivatives
EP3873470B1 (fr)	2022-05-18	Traitement et prévention de l'éjaculation précoce (pe)
US5177086A (en)	1993-01-05	Memory-enhancing compositions containing dioxopiperidine derivatives
US5276050A (en)	1994-01-04	Medicaments
AU2012201515B2 (en)	2015-01-29	5HT2C receptor modulator compositions and methods of use
PH26728A (en)	1992-09-28	The use of certain lactam derivatives in the treatment of depression
WO1998018469A1 (fr)	1998-05-07	Agents protecteurs des cellules des nerfs craniens
IL30966A (en)	1972-06-28	Phenylpropiophenones and method of using them
JPS6323969B2 (fr)	1988-05-18
HK40053063B (en)	2023-02-24	Treatment and prevention of premature ejaculation (pe)
HK40053063A (en)	2022-01-28	Treatment and prevention of premature ejaculation (pe)